<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202877</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0374</org_study_id>
    <secondary_id>NCI-2012-01896</secondary_id>
    <nct_id>NCT01202877</nct_id>
  </id_info>
  <brief_title>PKC412 and 5-Azacytidine</brief_title>
  <official_title>A Combination of PKC412 and 5-Azacytidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of PKC412 (also
      called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute
      leukemia and MDS. The safety and best dose of the combination of the drugs will also be
      studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      PKC412 is designed to block certain receptors (FLT3-Kinase) on cancer cells that are
      responsible for cancer growth. This may cause the cancer cells to die.

      5-azacytidine is designed to cause changes to certain genes that are thought to participate
      in causing leukemia. These changes are thought to silence these genes so they cannot
      contribute any longer to sustain the growth of leukemia and MDS.

      Study Groups:

      If you are found to be eligible to take part in this study, you will be assigned to a part of
      the study based on when you join.

        -  If you are one of the first 6 participants, you will receive a pre-planned dose of the
           study drugs. If 2 participants experience severe side effects, the rest of this group
           will receive a lower dose.

        -  If you are not one of the first 6 participants, and fewer than 2 patients had severe
           side effects in the first group, you will receive the drugs at a higher dose than the
           first 6 participants.

      Study Drug Administration:

      You will receive 5-azacytidine by vein over about 30 minutes or through a needle under your
      skin on Days 1-7 of each 28-day study cycle. Your doctor will decide if you will get the drug
      by vein or under the skin. You will be required to return to MD Anderson for the first 7 days
      of every cycle to receive 5-azacytidine.

      On Days 8-21 of cycle 1, you will take PKC412 capsules by mouth 2 times a day. Starting with
      Cycle 2, you will take PKC412 capsules by mouth every day. The research staff will tell you
      how to take the study drug and you will also be given instructions.

      If you have severe side effects from the study drug, the study doctor may decide to stop drug
      dosing until your side effects improve.

      Study Visits:

      At every visit, you will be asked about any side effects you have experienced and to list any
      drugs you may be taking.

        -  At the start of Cycles 1-2 (+/- 4 days) and then every 2-3 cycles, you will have a
           complete physical exam.

        -  Every week during Cycles 1-3 (+/- 4 days) and then every 2-4 weeks, blood (about 1
           tablespoon) will be drawn for routine tests and to test your kidney and liver function.

        -  On Day 28 of Cycle 1 (+/- 4 days) and then every 1-3 cycles, you will have a bone marrow
           aspirate to check the status of the disease.

        -  On Day 8 (+/- 1 day) of each cycle for the first cycle before initiation of Midostaurin,
           then before the start of Midostaurin on Cycle 2, then on Day 1 every 2-3 Cycles, you
           will have an ECG.

        -  On Days 8, 15, and 21 of Cycle 1 and Day 1 of Cycle 2, blood (about 1 teaspoon) will be
           drawn for PK testing before you take the study drug.

      If you stay on study for longer than 6 months, your doctor will decide what tests and
      procedures you will have and when they will be performed. At least every 6-12 months you will
      have a bone marrow aspirate.

      Length of Study:

      You may continue taking the study drug for as long as the doctor thinks it is in your best
      interest. You will no longer be able to take the study drug if the disease gets worse or
      intolerable side effects occur.

      This is an investigational study. PKC412 is not FDA approved or commercially available. It is
      currently being used for research purposes only. 5-azacytidine is FDA approved and
      commercially available for the treatment of patients with MDS. The combination of these drugs
      to treat refractory or relapsed acute leukemia and MDS is investigational.

      Up to 54 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Criteria for response per international working group for Myelodysplastic Syndrome (MDS) &amp; acute myeloid leukemia (AML) where responders obtained a complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%. Clinical responses evaluated using RECIST version 1.1 criteria after every two cycles, with confirmation of clinical response at 4 weeks after achieving response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response (OR) Within 6 Months</measure>
    <time_frame>6 Months</time_frame>
    <description>Overall response defined as percentage of participants with response as follows: (OR = CR [complete response (CR) rate] + CRi [complete remission with incomplete count recovery] + PR [partial remission] + HI [hematologic improvement]) within 6 months of treatment initiation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>5-azacytidine + PKC412</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-azacytidine</intervention_name>
    <description>Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.</description>
    <arm_group_label>5-azacytidine + PKC412</arm_group_label>
    <other_name>Azacitidine</other_name>
    <other_name>5-aza</other_name>
    <other_name>Vidaza</other_name>
    <other_name>5-AZC</other_name>
    <other_name>AZA-CR</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>NSC-102816</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PKC412</intervention_name>
    <description>Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
    <arm_group_label>5-azacytidine + PKC412</arm_group_label>
    <other_name>Midostaurin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with MDS, chronic myelomonocytic leukemia (CMML), AML or biphenotypic or
             bilineage leukemia who have failed prior therapy. Patients with MDS or CMML should
             have failed prior therapy with a hypomethylating agent and/or with lenalidomide.
             Patients with AML should have failed any prior induction therapy or have relapsed
             after prior therapy, or be previously untreated and unable or unwilling to receive
             conventional chemotherapy (e.g., patients age &gt;/=65 years). Patients with MDS or CMML
             who received therapy with a hypomethylating agent and progress to AML are eligible at
             the time of diagnosis of AML regardless any prior therapy for AML. The WHO
             classification will be used for AML. Patients with MDS, CMML or AML who have received
             no prior therapy are eligible if not candidates to receive or refuse standard therapy.

          2. Patients must have evidence of FLT3 activating mutations.

          3. Age &gt;/= 18 years

          4. Eastern Cooperative Oncology Group (ECOG) Performance Status &lt;/= 2

          5. Adequate liver (bilirubin &lt;/= 2x ULN, ALT &lt;/= 2.5x ULN) and renal (creatinine &lt;/= 2x
             ULN) function

          6. Patients must provide written informed consent.

          7. Patients must have been off chemotherapy for 2 weeks prior to entering this study,
             unless there is evidence of rapidly progressive disease, and must have recovered from
             the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients
             with rapidly proliferative disease is allowed before the start of study therapy and
             for the first four weeks on therapy.

          8. Women of childbearing potential must practice contraception. Women considered not of
             childbearing potential include any of the following: no menses for at least 5 years or
             menses within 5 years but amenorrheic for at least 2 months and luteinizing hormone
             (LH) and follicular stimulating hormone (FSH) values within normal range (according to
             definition of postmenopausal for laboratory used) or bilateral oophorectomy or
             radiation castration and amenorrheic for at least 3 months. Females of childbearing
             potential: Recommendation is for 2 effective contraceptive methods during the study.
             Adequate forms of contraception are double barrier methods (condoms with spermicidal
             jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or
             injectable contraceptives, intrauterine devices, and tubal ligation.

          9. **continued from above: Male patients with female partners who are of childbearing
             potential: Recommendation is for male and partner to use at least 2 effective
             contraceptive methods, as described above, during the study.

         10. Sexually active males should use a condom during intercourse while taking drug and for
             3 months after stopping midostaurin medication. They should not father a child in this
             period. A condom is required to be used also by vasectomized men in order to prevent
             delivery of the drug via seminal fluid .

         11. Negative urine or serum pregnancy test within 2 weeks.

        Exclusion Criteria:

          1. Patients with known allergy or hypersensitivity to PKC412, mannitol or 5-azacytidine,
             or any of their components.

          2. Patients who have received any treatment of midostaurin prior to study entry.

          3. Patients with known impairment of gastrointestinal (GI) function or GI disease that
             may significantly alter the absorption of PKC412.

          4. Patients who demonstrated primary resistance to any FLT3 inhibitor or who relapsed
             while on therapy with a FLT3 inhibitor.

          5. Patients with any other known disease (except carcinoma in-situ) concurrent severe
             and/or uncontrolled medical condition (e.g. uncontrolled diabetes with fasting glucose
             &gt; 200 mg/dl despite optimal management, cardiovascular disease including congestive
             heart failure (NYHA Class III or IV), myocardial infarction within 6 months and poorly
             controlled hypertension with systolic &gt; 160 mmHg and diastolic &gt; 100 mmHg, chronic
             renal disease, or active uncontrolled systemic infection) which could compromise
             participation in the study.

          6. Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.
             HIV patients not on specific antiretroviral therapy are eligible for participation.

          7. Patients who have had any major surgical procedure within 14 days of Day 1.

          8. Patients unwilling or unable to comply with the protocol.

          9. Patients with known advanced malignant disease of the central nervous system.

         10. Impaired cardiac function including any of the following: Screening ECG with a
             corrected QT interval (QTc) &gt; 470 msec; Patients with congenital long QT syndrome;
             History or presence of sustained ventricular tachycardia; Any history of ventricular
             fibrillation or torsades de pointes; Bradycardia defined as HR &lt; 50 bpm; Right bundle
             branch block + left anterior hemiblock (bifascicular block); Patients with myocardial
             infarction or unstable angina &lt; 6 months prior to starting study drug; congestive
             heart failure (CHF) NY Heart Association class III or IV; Patients with an ejection
             fraction &lt; 50% assessed by multigated radionuclide angiography (MUGA) or ECHO scan
             within 14 days of Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>September 16, 2016</results_first_submitted>
  <results_first_submitted_qc>September 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2016</results_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Refractory acute leukemias</keyword>
  <keyword>Relapsed acute leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>5-Azacytidine</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>5-aza</keyword>
  <keyword>Vidaza</keyword>
  <keyword>5-AZC</keyword>
  <keyword>AZA-CR</keyword>
  <keyword>Ladakamycin</keyword>
  <keyword>NSC-102816</keyword>
  <keyword>PKC412</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Midostaurin</mesh_term>
    <mesh_term>Staurosporine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: March 2, 2011 to October 01, 2013. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>There were 57 participants for enrollment, one participant was a screen failure and two withdrew consent without receiving the study drug treatment and are therefore excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
          <description>5-azacytidine 75 mg/m2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="P2">
          <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
          <description>5-azacytidine 75 mg/m2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="P3">
          <title>Phase II: 5-azacytidine + PKC412</title>
          <description>AZA 75 mg/m^2 on days 1-7 and Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
          <description>5-azacytidine (AZA) 75 mg/m^2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="B2">
          <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
          <description>AZA 75 mg/m^2/day SQ or IV on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="B3">
          <title>Phase II: 5-azacytidine + PKC412</title>
          <description>AZA 75 mg/m^2 on days 1-7 and Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="40" upper_limit="68"/>
                    <measurement group_id="B2" value="62" lower_limit="38" upper_limit="85"/>
                    <measurement group_id="B3" value="67" lower_limit="21" upper_limit="83"/>
                    <measurement group_id="B4" value="65" lower_limit="21" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</title>
        <description>Criteria for response per international working group for Myelodysplastic Syndrome (MDS) &amp; acute myeloid leukemia (AML) where responders obtained a complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%. Clinical responses evaluated using RECIST version 1.1 criteria after every two cycles, with confirmation of clinical response at 4 weeks after achieving response.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
            <description>AZA 75 mg/m^2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
          </group>
          <group group_id="O2">
            <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
            <description>AZA 75 mg/m^2/day SQ or IV on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
          </group>
          <group group_id="O3">
            <title>Phase II: 5-azacytidine + PKC412</title>
            <description>AZA 75 mg/m^2 on days 1-7 and PKC412 Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</title>
          <description>Criteria for response per international working group for Myelodysplastic Syndrome (MDS) &amp; acute myeloid leukemia (AML) where responders obtained a complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%. Clinical responses evaluated using RECIST version 1.1 criteria after every two cycles, with confirmation of clinical response at 4 weeks after achieving response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete w/Incomplete Bone Marrow Recovery (CRi)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphologic Leukemia-Free Status (MLFS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Remission (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Response (OR) Within 6 Months</title>
        <description>Overall response defined as percentage of participants with response as follows: (OR = CR [complete response (CR) rate] + CRi [complete remission with incomplete count recovery] + PR [partial remission] + HI [hematologic improvement]) within 6 months of treatment initiation</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-azacytidine + PKC412</title>
            <description>5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
5-azacytidine: Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
PKC412: Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response (OR) Within 6 Months</title>
          <description>Overall response defined as percentage of participants with response as follows: (OR = CR [complete response (CR) rate] + CRi [complete remission with incomplete count recovery] + PR [partial remission] + HI [hematologic improvement]) within 6 months of treatment initiation</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events captured from the time of the first protocol-specific intervention with each 21 day cycle until 30 days after the last dose of drug, about 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
          <description>AZA 75 mg/m^2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="E2">
          <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
          <description>AZA 75 mg/m^2/day SQ or IV on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="E3">
          <title>Phase II: 5-azacytidine + PKC412</title>
          <description>AZA 75 mg/m^2 on days 1-7 and PKC412 Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutropenia Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection of blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Left Ventricular systolic dysfuction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cardiac Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain (General)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Progressive Disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain, Bone/Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complication Surgical medical procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection from catheter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="40" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Abnormal Absolute Neutrophile Count</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="40" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QTc prolongation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="40" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Platelet Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="40" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Prolongation of QT interval</sub_title>
                <description>Electrocardiogram QT corrected interval prolonged</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abnormal liver function test (LFT)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Cortes, MD/Professor, Leukemia</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>1-877-632-6789</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

